

In 2012 Almost 24,000 Allografts Were Sterilized (SAL6)* Utilizing NovaSterilis Supercritical CO₂ Process

LANSING, NY April 15, 2013 – **NovaSterilis Inc.**, which specializes in developing commercial applications for supercritical carbon dioxide (SCCO₂), has achieved a milestone for the company's allograft tissue sterilization technology. During 2012 almost 24,000 units of allograft tissue, including tendons and bone were terminally sterilized using their patented process.

For **NovaSterilis** this milestone quantifies the steady growth and market acceptance of SCCO₂ tissue sterilization. The first supercritical CO₂-sterilized tissue was introduced in the US market in 2009, a significant advancement in the industry. Later that year Australian Biotechnologies received regulatory approval to market a SCCO₂-sterilized cortical and cancellous bone product, which was launched later that year throughout Australia. In 2010 two additional US-based tissue banks adopted the technology and expanded its use to multiple products including bone and tendon. **NovaSterilis** recently licensed the process to a European-based tissue processor and contract manufacturer for product distribution in Europe, India, China and Malaysia.

This important milestone notwithstanding, **NovaSterilis** remains committed to increasing the quality and safety of the global allograft tissue market, which is the primary concern of transplant surgeons and patients. **NovaSterilis's** patented supercritical CO₂ terminal sterilization process achieves an industry standard Sterility Assurance Level 10⁻⁶ (SAL6)* while fully maintaining the structural and mechanical integrity of these tissues.

“The benefit of using supercritical CO₂ is that it has virtually no effect on collagen, which is the major structural component of all tissues,” stated David Burns, NovaSterilis President. “Our partners are producing the highest quality, safest tissue available, which is the proper way to honor the organ and tissue donation.”

Recent experiments with larger scale SCCO₂ units have provided important data supporting the scale-up of this technology to meet the high throughput needs of customers. NovaSterilis's SCCO₂ process provides the medical materials industry with a safe, effective, in house, low cost terminal sterilization alternative.

Learn more about supercritical CO₂ sterilization at www.novasterilis.com

About NovaSterilis

NovaSterilis currently markets terminal sterilization technology and equipment related to their supercritical carbon dioxide platform. The supercritical or fluid phase of CO₂, occurs at low pressure (72.9 atm) and moderate temperatures (31.1 °C). SCCO₂ retains advantageous properties of the gas and liquid phases of carbon dioxide making it an ideal fluid for manufacturing processes. The company currently markets the Nova 2200, a 20 liter fully automated SCCO₂ terminal sterilization chamber and the Nova8800 an 80 liter unit. NovaSterilis is a privately held biotechnology company located in Lansing New York. NovaSterilis is the recipient of a 2007 Presidential Green Chemistry Challenge Award presented by the Environmental Protection Agency.

* (SAL6) – Sterility Assurance Level 10⁻⁶ is a standard for medical devices. It is the probability of 1 non-sterile item in 1 million. For more information on NovaSterilis and supercritical carbon dioxide visit www.novasterilis.com